Industry & Policy News

[University of Colorado] At the first inkling of a creaky knee, patients could get a single shot in the joint that would not only stop their cartilage and bone from eroding, but kick start its regrowth. That may seem like a dream, but the Advanced Research Projects Agency for Health awarded up to $39 million to a University of Colorado Boulder-led team of scientists to work toward making it a reality.

[Science] A cohort of transgenic marmoset models may help predict neurological conditions and test potential treatments.

[UMass Chan Medical School] UMass Chan Medical School and Lahey Hospital & Medical Center have signed a research affiliation agreement to create a new quantitative science research hub to improve health outcomes and disparities through population health, digital medicine and health systems science.

[Global News] The Children’s Hospital Research Institute of Manitoba has announced its new research theme, which will focus on kids with cancer in support of the Children’s Hospital of Manitoba.

[Innovent Biologics, Inc.] Innovent Biologics, Inc. announced that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase III clinical trial, for resectable mismatch repair deficient colon cancer neoadjuvant therapy.

[The University of Texas at Tyler] The University of Texas at Tyler received a $447,195 grant from the National Institutes of Health to support the research of Dr. May Abdelaziz, Ben and Maytee Fisch College of Pharmacy assistant professor, in HER2, a protein that promotes the growth of breast cancer.